Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
| Autor: | Toshinari Yamashita, Yoshie Hasegawa, Masaya Hattori, Seigo Nakamura, Eriko Tokunaga, Miki Yamaguchi, Shoichiro Ohtani, Hidetoshi Kawaguchi, Satoshi Morita, Takahiro Nakayama, Nobuaki Sato, Keisei Anan, Daisuke Yotsumoto, Masakazu Toi, Kenjiro Aogi, Tomomi Fujisawa, Norikazu Masuda, Shinji Ohno, Yutaka Yamamoto, Hiroko Yamashita, Yoshinori Ito, Toshimi Takano, Shigehira Saji |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Antineoplastic Agents Hormonal Receptor ErbB-2 medicine.drug_class Post-menopause Estrogen receptor Breast Neoplasms Breast cancer Surgical oncology Internal medicine Antineoplastic agents medicine Humans Overall survival Pharmacology (medical) Radiology Nuclear Medicine and imaging Fulvestrant Aged Retrospective Studies Aged 80 and over Proportional hazards model business.industry Carcinoma Ductal Breast Cancer General Medicine Middle Aged Prognosis medicine.disease Hormones Postmenopause Survival Rate Carcinoma Lobular Receptors Estrogen Estrogen Original Article Female Neoplasm Recurrence Local Receptors Progesterone business Follow-Up Studies medicine.drug Cohort study |
| Zdroj: | Breast Cancer (Tokyo, Japan) |
| ISSN: | 1880-4233 1340-6868 |
| Popis: | Background Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a retrospective, multicenter cohort study involving 1072 Japanese patients receiving fulvestrant 500 mg mostly as a second- or later-line endocrine therapy for ER+ ABC. The follow-up data after the Safari study were examined, focusing on any relationship between clinicopathological factors and overall survival (OS) in ER+ ABC patients. Methods OS in patients with ER+ ABC was analyzed by univariate and multivariate analyses with a Cox proportional hazards model in this study. Results A total of 1031 cases were evaluable for OS analysis. Multivariate analysis showed that younger age ( Conclusions In ER+ ABC patients whose treatment history included fulvestrant, younger age, longer time from ABC diagnosis to fulvestrant use, no prior palliative chemotherapy use, PgR−, and lower histological or nuclear grade correlated positively with prolonged OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink